ORIC
insider transactionsOric Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-58.7K
0 buy · 58.7K sell
Net value · 365d
-$783.1K
$0 in · $783.1K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
3
0 buy · 58.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Financial Officer · 10b5-1
$0
52.0K sh
Own +56%
-
Sell·S
Chief Financial Officer · 10b5-1
$702.7K
52.0K sh · $13.51
Own -43%
-
Exercise·M
Chief Financial Officer · 10b5-1
$226.7K
52.0K sh · $4.36
Own +76%
-
Sell·S
Director · 10b5-1
$38.4K
3.2K sh · $12.00
Own -1%
-
Sell·S
Director · 10b5-1
$42.0K
3.5K sh · $12.00
Own -8%
-
Grant·A
Chief Financial Officer
$0
34.5K sh
Own New
-
Grant·A
Chief Financial Officer
$0
206.5K sh
Own New
-
Grant·A
Director
$0
40.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
35.5K sh
Own New
-
Grant·A
Chief Medical Officer
$0
214.0K sh
Own New
-
Grant·A
Director
$0
40.0K sh
Own New
-
Grant·A
Director
$0
40.0K sh
Own New
-
Grant·A
Jacob Chacko KEY
PRESIDENT AND CEO
$0
112.5K sh
Own New
-
Grant·A
Jacob Chacko KEY
PRESIDENT AND CEO
$0
675.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 24, 2026 | Dominic Piscitelli KEY 10b5-1 | Exercise M | 52.0K | $0 |
| Feb 24, 2026 | Dominic Piscitelli KEY 10b5-1 | Sell S | 52.0K | $702.7K |
| Feb 24, 2026 | Dominic Piscitelli KEY 10b5-1 | Exercise M | 52.0K | $226.7K |
| Jan 16, 2026 | Richard A. Heyman 10b5-1 | Sell S | 3.2K | $38.4K |
| Jan 16, 2026 | Richard A. Heyman 10b5-1 | Sell S | 3.5K | $42.0K |
| Jan 2, 2026 | Dominic Piscitelli KEY | Grant A | 34.5K | $0 |
| Jan 2, 2026 | Dominic Piscitelli KEY | Grant A | 206.5K | $0 |
| Jan 2, 2026 | Angie You | Grant A | 40.0K | $0 |
| Jan 2, 2026 | Pratik S Multani | Grant A | 35.5K | $0 |
| Jan 2, 2026 | Pratik S Multani | Grant A | 214.0K | $0 |
| Jan 2, 2026 | Lori Anne Kunkel | Grant A | 40.0K | $0 |
| Jan 2, 2026 | Richard A. Heyman | Grant A | 40.0K | $0 |
| Jan 2, 2026 | Jacob Chacko KEY | Grant A | 112.5K | $0 |
| Jan 2, 2026 | Jacob Chacko KEY | Grant A | 675.0K | $0 |
About ORIC insider trading
This page tracks insider transactions for Oric Pharmaceuticals, Inc. (ORIC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.